EP Patent

EP4687898A1 — Compositions and methods for administering paltusotine to patients with hepatic impairment

Assigned to Crinetics Pharmaceuticals Inc · Expires 2026-02-11 · 0y expired

What this patent protects

Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.

USPTO Abstract

Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP4687898A1
Jurisdiction: EP
Classification: —
Expires: 2026-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Crinetics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.